A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.

Simon Rule,Sabine Kayser,Lisa Drew,Martin Js Dyer,Andrew Davies,Joe Birkett,Arnon P Kater,Martin Kaiser,Tim H Brümmendorf,Chris Fegan,Wolfram Brugger,Stephan Stilgenbauer,Peter Brossart,John A Radford,Wenlin Shao,Justin Cidado

doi:10.1200/jco.2018.36.15_suppl.tps7588

A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.

Simon Rule, Sabine Kayser + Show 14 more

https://doi.org/10.1200/jco.2018.36.15_suppl.tps7588

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 9

Affiliation: Derriford Hospital, Heidelberg University, AstraZeneca (United States), University of Leicester, University of Southampton, Cancer Research UK, University of Amsterdam, Royal Marsden Hospital, Universitätsklinikum Aachen, University Hospital of Wales, AstraZeneca (United Kingdom), University of Ulm, University Hospital Bonn, The Christie NHS Foundation Trust

#Selective Cyclin-dependent Kinase 9 Inhibitor #Cyclin-dependent Kinase 9 + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

TPS7588Background: Cyclin-dependent kinase 9 (CDK9) belongs to the group of transcription-regulating CDKs and promotes transcription elongation through phosphorylation of RNA Polymerase II at serin...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.